Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

The interest in the obesity treatment landscape among pharmaceutical companies also leads Citi to consider BioAge Labs as a possible target for mergers and acquisitions, should the drug's proof-of ...

As of the last twelve months ending Q2 2024, BioAge's market capitalization stands at $854.6 million, reflecting investor interest in its innovative approach to treating obesity. Despite the positive ...

Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today announced ...

The interest in the obesity treatment landscape among pharmaceutical companies also leads Citi to consider BioAge Labs as a possible target for mergers and acquisitions, should the drug's ...